OakChart

Gossamer Bio Inc

GOSSHealthcare·Biotechnology·USA·Micro·NASD·Nov 11 • 3:06 PM ET

11.24-0.04 (-0.35%)
2026-11-11 21:07 CET
Market cap
68.93 USD m
Revenue, TTM
78.42 USD m
Net income, TTM
-125.07 USD m
Free cash flow, TTM
-158.00 USD m
EPS diluted, TTM
-46.11
P/E
-
Compare

Price

GOSS against its 20, 50 and 200-day averages
2050200beatmiss
0.0050.00100.00150.002.2M4.5MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26GOSSclose 11.2420-day 9.8150-day 10.67200-day 33.1011.24

96.4% under the 52-week high of 309.60 on 15 Dec 2025. 52-week low 8.29 on 20 Oct 2026. Last 15 sessions, 33.6% high to low

Volume 0.92× normal · the line is the 50-bar volume average

Profile

GOSS
52-week range, 1% of the way up
8.29309.6

Gossamer Bio, Inc. engages in discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. Its primary product candidate, GB001, is intended for the treatment of moderate-to-severe eosinophilic asthma and other allergic conditions. The company was founded by Faheem Hasnain and Sheila Gujrathi on October 26, 2015 and is headquartered in San Diego, CA.

Employees162
IPOFeb 08, 2019
Beta2.24
ATR, 14d1.06
Rel volume0.92
Short float23.91%
Insider own8.34%
Inst own80.22%

Snapshot

6 groups

Valuation

Index-
Market Cap68.69M
Enterprise Value58.35M
Income-125.07M
Sales78.42M
Book/sh-20.08
Cash/sh8.38
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees162
IPOFeb 08, 2019

Ratios

P/E-
Forward P/E-
PEG-
P/S0.88
P/B-
P/C1.34
P/FCF-
EV/EBITDA-
EV/Sales0.74
Quick Ratio0.60
Current Ratio0.60
Debt/Eq-
LT Debt/Eq-
Option/ShortNo / Yes

Earnings

EPS (ttm)-46.11
EPS next Y-6.32
EPS next Q-2.87
EPS this Y74.08%
EPS next Y59.40%
EPS next 5Y59.47%
EPS past 3/5Y34.98% 26.82%
Sales past 3/5Y- -
EPS Y/Y TTM7.41%
Sales Y/Y TTM78.03%
EPS Q/Q56.49%
Sales Q/Q189.09%
EarningsNov 10 AMC
EPS/Sales Surpr.-94.12% 216.00%

Ownership

Insider Own8.34%
Insider Trans0.00%
Inst Own80.22%
Inst Trans56.39%
ROA-91.58%
ROE-
ROIC-
Gross Margin98.81%
Oper. Margin-136.46%
Profit Margin-159.49%
SMA2014.55%
SMA505.38%
SMA200-66.05%
Trades-

Technical

Shs Outstand6.12M
Shs Float5.60M
Short Float23.91%
Short Ratio5.22
Short Interest1.34M
52W High309.60 -96.37%
52W Low8.29 35.59%
Volatility11.20% 9.53%
ATR (14)1.06
RSI (14)58.29
Beta2.24
Rel Volume0.92
Avg Volume256.36K
Volume204,319

Performance

Perf Week12.96%
Perf Month15.16%
Perf Quarter-17.50%
Perf Half Y-59.11%
Perf YTD-95.47%
Perf Year-94.58%
Perf 3Y-73.18%
Perf 5Y-98.86%
Perf 10Y-
Recom2.25
Target Price83.40
Prev Close11.28
Price11.24
Change %-0.35%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Oct 13, 2026InitiatedCChardan Capital MarketsBuy$160+1,323.5%
Jul 28, 2026UpgradeLLeerink PartnersMarket Perform → Outperform$1-91.1%
Mar 23, 2026DowngradeCCantor FitzgeraldOverweight → Neutral
Feb 24, 2026DowngradeWWedbushOutperform → Neutral$1-91.1%
Feb 24, 2026DowngradeLLeerink PartnersOutperform → Market Perform$1-91.1%
Feb 24, 2026DowngradeBBarclaysOverweight → Equal Weight$0.30-97.3%
Jan 28, 2026InitiatedBBarclaysOverweight$9-19.9%
Sep 10, 2025UpgradeUUBSNeutral → Buy$9-19.9%
Jul 14, 2025InitiatedBScotiabankSector Outperform$11-2.1%
Jun 25, 2024InitiatedOOppenheimerOutperform$9-19.9%

Peers

Mkt cap
TickerCompanyMkt cap
TENXTenax Therapeutics Inc76.96M
INSMInsmed Inc26.24B
UTHRUnited Therapeutics Corp25.43B
LQDALiquidia Corp4.88B
MNKDMannkind Corp1.34B
ROIVRoivant Sciences Ltd30.32B
KROSKeros Therapeutics Inc186.63M
SVRASavara Inc1.11B
MRKMerck & Co Inc361.04B
JNJJohnson & Johnson674.50B

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IBBiShares Biotechnology ETFAUM: 11.36B
VHTVanguard Health Care ETFAUM: 21.51B
PRFZInvesco RAFI US 1500 Small-Mid ETFAUM: 2.66B
ESSCEventide Small Cap ETFAUM: 33.70M
IBBQInvesco Nasdaq Biotechnology ETFAUM: 130.27M
BIBProShares Ultra Nasdaq Biotechnology 2X SharesAUM: 107.35M

News

latest 14 of 200

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-10-7.360-3.791-7.36038.4312.167
2026Q22026-08-13-6.400-9.874-6.1249.243.637
2026Q12026-05-18-16.000-13.240-15.94416.964.678
2025Q42026-03-17-16.800-15.656-16.67713.807.529
2025Q32025-11-05-16.800-15.304-16.92113.296.388
2025Q22025-08-05-13.600-14.168-13.47211.495.4110
2025Q12025-05-15-12.800-14.968-12.9229.894.078
2024Q42025-03-13-12.000-13.600-11.6619.386.838
2024Q32024-11-07-11.200-11.776-10.8879.488.5310
2024Q22024-08-1217.60040.53616.51195.84114.296
2024Q12024-05-07-15.200-15.208-14.8590.000.009
2023Q42024-03-05-16.800-16.664-17.0880.000.009
2023Q32023-11-09-16.800-20.520-16.5940.000.0010
2023Q22023-08-08-36.000-39.136-35.6180.000.0010
2023Q12023-05-09-41.600-42.400-41.4580.000.0010
2022Q42023-03-17-47.200-49.840-47.3180.000.0013

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-263.2-254.51-263.510.000.00
2020FY-284-276-284.170.000.00
2021FY-250.4-245.24-250.130.000.00
2022FY-216.8-220.18-216.970.000.00
2023FY-94.400-99.480-94.2550.000.00
2024FY-20.000-22.600-19.990114.7112.15
2025FY-60.000-59.316-60.00048.4742.20
2026FY--15.553--55.11
2027FY--6.315--18.76
2028FY--3.995--82.82
2029FY-0.810--165.99
2030FY-7.062--272.91

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-117003.010.0021.10
2026Q4S2026-11-107003.010.0021.10
2026Q4S2026-11-087003.010.0021.10
2026Q4S2026-10-287013.010.0021.10
2026Q4S2026-10-107033.010.0021.10
2026Q4S2026-10-097043.010.0021.10
2026Q4S2026-10-076040.000.000.00
2026Q4S2026-08-256050.000.000.00
2026Q4S2026-08-146043.000.0018.00
2026Q4S2026-08-046036.080.0018.00
2026Q4S2026-08-016136.080.0018.00
2026Q4S2026-07-276236.080.0018.00
2026Q4S2026-07-246226.910.0018.00
2026Q4S2026-06-296217.750.0018.00

Estimate history

EPS, annual-8.224-178.481-263.51-284.174-250.126-216.97-94.255-19.99-59.643-46.1065
Period201720182019202020212022202320242025TTM
EPS, quarterly-10.887-11.661-12.922-13.472-16.921-16.677-15.944-6.124-7.362
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual0000000114.70148.47178.42
Period201720182019202020212022202320242025TTM
Sales, quarterly9.489.3799.88911.48913.29413.79916.9559.23838.431
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual0.8230.8230.770.9230.9471.182.8182.8332.9216.116
Period201720182019202020212022202320242025MRQ
Shares, quarterly2.8332.8332.842.8422.8912.9212.9346.1116.116
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue78.4248.47114.700.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.941.004.154.384.435.174.273.090.30
Gross Profit77.4947.47110.55-4.38-4.43-5.17-4.27-3.09-0.30
Selling, General and Administrative Excl. Other184.50210.72170.47169.37214.10208.48206.31179.4599.04
Research and Development137.23174.07137.65133.70169.09166.84158.00143.4055.28
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-107.01-163.25-59.92-173.76-218.53-213.65-210.58-182.54-99.33
Interest Expense10.6810.9911.5213.5113.8819.4412.67-0.01
Unusual Expense4.177.470.0010.000.072.4823.383.6049.66
Net Income Before Taxes-125.16-170.46-55.63-179.82-229.38-234.00-243.36-180.31-146.97
Income Taxes-0.09-0.090.890.000.000.000.000.000.00
Consolidated Net Income-125.07-170.37-56.53-179.82-229.38-234.00-243.36-180.31-146.97
Net Income From Continuing Operations-125.07-170.37-56.53-179.82-229.38-234.00-243.36-180.31-146.97
Net Income-125.07-170.37-56.53-179.82-229.38-234.00-243.36-180.31-146.97
EPS (Recurring)-25.15-57.81-19.99-90.59-216.93-248.27-265.06-259.83-136.27
EPS (Basic, Before Extraordinaries)-35.76-59.64-19.99-94.26-216.97-250.13-284.17-263.51-178.48
EPS (Diluted)-46.11-59.64-19.99-94.26-216.97-250.13-284.17-263.51-178.48
EBITDA-106.08-162.25-55.77-169.37-214.10-208.48-206.31-179.45-99.04
Non-Operating Income (Expense)-3.3011.2615.8017.453.101.563.275.832.04
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense15.468.3416.2928.5242.5532.0138.7520.8230.95
Price To Sales Ratio0.9914.621.78------
Gross Margin98.8197.9396.38------
Operating Margin-136.46-336.81-52.24------
Net Margin-159.49-351.49-49.28------
Shares Outstanding6.122.922.832.821.180.950.920.770.82
Market Capitalization68.9368.93204.99205.69203.79856.76714.37963.36936.12

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue38.439.2416.9513.8013.2911.499.899.38
Cost of Goods Sold Incl. D&A0.230.250.230.230.220.210.341.07
Gross Profit38.208.9916.7213.5713.0711.289.558.30
Selling, General and Administrative Excl. Other28.2435.0661.5959.6154.7150.0446.3644.43
Research and Development18.8226.4143.0748.9345.5441.5738.0336.00
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income9.97-26.07-44.87-46.04-41.64-38.77-36.81-36.13
Interest Expense2.462.712.752.752.752.742.752.74
Unusual Expense53.73-49.560.00-0.007.480.000.000.00
Net Income Before Taxes-48.0716.90-46.66-47.33-48.22-38.27-36.64-35.44
Income Taxes0.000.000.00-0.090.000.000.00-2.41
Consolidated Net Income-48.0716.90-46.66-47.24-48.22-38.27-36.64-33.03
Net Income From Continuing Operations-48.0716.90-46.66-47.24-48.22-38.27-36.64-33.03
Net Income-48.0716.90-46.66-47.24-48.22-38.27-36.64-33.03
EPS (Recurring)-1.60-14.57-15.94-16.68-15.08-13.47-12.92-11.66
EPS (Basic, Before Extraordinaries)-7.364.22-15.94-16.68-16.92-13.47-12.92-11.66
EPS (Diluted)-7.36-6.12-15.94-16.68-16.92-13.47-12.92-11.66
EBITDA10.19-25.82-44.63-45.81-41.42-38.55-36.47-35.05
Non-Operating Income (Expense)-1.84-3.880.961.463.643.242.923.43
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense3.792.466.302.902.672.592.403.92
Price To Sales Ratio0.991.021.3814.4913.616.952.001.79
Gross Margin99.4197.2798.6398.3598.3598.1596.5488.54
Operating Margin25.93-282.25-264.62-333.65-313.21-337.41-372.23-385.20
Net Margin-125.09182.94-275.22-342.33-362.73-333.13-370.49-352.16
Shares Outstanding6.126.112.932.922.892.842.842.83
Market Capitalization68.9380.4677.10724.40608.34279.61249.94204.99

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments136.93294.52296.43255.68325.28513.19401.83228.860.32
Short Term Receivables12.535.540.000.000.200.201.500.000.00
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets18.189.8310.096.206.308.935.993.100.13
Total Current Assets167.64309.89306.52261.88331.78522.32409.32231.950.45
Net Property, Plant & Equipment4.205.124.789.8910.8016.0815.733.190.00
Total Investments and Advances0.000.000.000.000.000.000.000.000.00
Intangible Assets-------0.000.00
Other Assets0.410.280.620.681.081.031.564.270.00
Total Assets172.25315.29311.92272.45343.66539.43426.60239.420.45
Short Term Debt Incl. Current Port. of LT Debt0.940.9614.9114.602.903.632.350.000.00
Accounts Payable5.962.325.531.463.247.510.962.180.00
Income Tax Payable0.01--------
Other Current Liabilities56.5341.7331.1633.1733.7127.5133.6118.221.27
Total Current Liabilities63.4445.0151.6049.2339.8638.6536.9220.401.27
Long Term Debt201.97201.92197.55211.14182.34180.1037.200.006.04
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities29.6138.870.000.000.000.000.000.720.00
Total Liabilities295.01285.80249.15260.37222.19218.7574.1221.127.31
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.00338.370.00
Common Equity-122.7629.4962.7712.08121.46320.68352.49-120.07-6.86
Total Shareholders Equity-122.7629.4962.7712.08121.46320.68352.49218.30-6.86
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity-122.7629.4962.7712.08121.46320.68352.49218.30-6.86
Total Liabilities & Stockholders Equity172.25315.29311.92272.45343.66539.43426.60239.420.45
Book Value Per Share-42.0310.4122.2810.23128.27347.27457.51-145.81-8.33
Tangible Book Value Per Share-42.0310.4122.2810.23128.27347.27457.51-145.81-8.33
Full-Time Employees16214513517818519517111911
Price to Book Ratio-0.736.951.973.627.052.232.732.35-
Return on Assets-69.89-18.03-61.54-74.46-53.00-50.38-54.14-122.54-2,681.58
Return on Equity--122.54-480.50-343.53-105.85-72.30-63.18-139.02-
Return on Invested Capital-215.09-24.43-69.08-102.76-77.03-48.60-46.27-67.32-
Quick Ratio2.646.885.945.328.3213.5111.0911.370.35
Current Ratio2.646.885.945.328.3213.5111.0911.370.35

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-125.07-170.37-56.53-179.82-229.38-234.00-243.36-180.31-146.97
Depreciation0.941.004.154.384.435.174.273.090.30
Other Funds (Non Cash)24.1311.739.4531.1142.3839.1765.8322.2680.61
Funds from Operations-100.01-157.64-42.93-144.32-182.57-189.66-173.26-154.95-66.07
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-57.99-13.6339.46-14.84-4.460.77-3.1010.1215.02
Cash from Operating Activities-158.00-171.27-3.47-159.16-187.03-188.89-176.36-144.83-51.04
Capital Expenditures0.00-0.080.000.00-0.41-1.55-1.50-2.97-3.49
Net Assets From Acquisitions0.000.000.000.00-0.07-0.07-23.38-3.60-17.72
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.00-
Purchase or Sale of Investments173.36156.4429.02-110.97-0.56-115.81240.22-140.58-123.50
Purchase of Investments-45.98-227.11-494.78-441.67-238.06-152.03-108.97-499.08-123.50
Sale Or Maturity of Investments219.34383.54523.80330.70237.5036.23349.19358.50-
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities173.36156.3629.02-110.97-1.03-117.43215.34-147.14-144.71
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock27.006.421.09201.77122.903.33117.64293.360.00
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock27.006.421.09201.77122.903.33117.64293.360.00
Proceedsfrom Stock Options0.020.841.09201.77121.160.00117.11291.310.00
Issuance or Reduction of Debt, Net0.000.00-12.58-11.61-5.810.00193.6028.22300.86
Change in Long Term Debt0.000.00-12.58-11.61-5.810.00193.6028.22300.86
Issuance of Long Term Debt0.000.000.000.000.000.00193.6028.22300.90
Reduction of Long Term Debt0.000.00-12.58-11.61-5.810.000.000.00-0.04
Net Financing Active Other Cash Flow0.000.000.000.000.000.001.300.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities27.006.42-11.49190.15117.093.33312.54321.58300.86
Exchange Rate Effect-0.110.14-0.100.11-0.52-0.170.010.07-
Net Change in Cash42.26-8.3413.96-79.86-71.49-303.15351.5329.67105.10
Free Cash Flow-158.00-171.34-3.47-159.16-187.44-190.44-177.86-147.80-54.53
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments51.1957.0399.22136.93180.22212.92
Short Term Receivables0.006.119.3512.539.647.98
Inventories0.000.000.000.000.000.00
Other Current Assets9.249.5915.9718.1814.1215.00
Total Current Assets60.4372.72124.54167.64203.99235.90
Net Property, Plant & Equipment3.493.713.964.204.424.64
Total Investments and Advances0.000.000.000.000.000.00
Other Assets0.420.430.400.410.410.38
Total Assets64.3476.87128.90172.25208.82240.93
Short Term Debt Incl. Current Port. of LT Debt38.1637.110.960.940.920.89
Accounts Payable1.475.9510.825.961.121.88
Income Tax Payable0.010.010.010.01--
Other Current Liabilities60.3194.7244.7256.5360.0850.83
Total Current Liabilities99.94137.7856.5163.4462.1253.59
Long Term Debt2.692.96201.98201.97201.96201.94
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities84.4930.1631.9029.6127.0831.50
Total Liabilities187.13170.90290.38295.01291.15287.03
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity-122.80-94.03-161.48-122.76-82.33-46.11
Total Shareholders Equity-122.80-94.03-161.48-122.76-82.33-46.11
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity-122.80-94.03-161.48-122.76-82.33-46.11
Total Liabilities & Stockholders Equity64.3476.87128.90172.25208.82240.93
Book Value Per Share-20.08-15.39-55.04-42.03-28.48-16.23
Tangible Book Value Per Share-20.08-15.39-55.04-42.03-28.48-16.23
Full-Time Employees---162--
Price to Book Ratio-0.73-0.86-0.48-5.90-7.39-6.06
Return on Assets-91.58-78.81-88.11-69.89-55.80-45.17
Return on Equity------783.37
Return on Invested Capital---115.24-59.64-40.31-24.56
Quick Ratio0.600.532.202.643.284.40
Current Ratio0.600.532.202.643.284.40

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-48.0716.90-46.66-47.24-48.22-38.27
Depreciation0.230.250.230.230.220.21
Other Funds (Non Cash)60.67-44.505.902.068.800.89
Funds from Operations12.82-27.35-40.53-44.95-39.20-37.17
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-42.40-14.041.81-3.363.03-9.89
Cash from Operating Activities-29.58-41.39-38.72-48.31-36.17-47.06
Capital Expenditures0.000.000.000.000.00-0.05
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments15.9042.7041.6173.1617.0144.18
Purchase of Investments0.000.00-24.99-20.99-29.59-75.52
Sale Or Maturity of Investments15.9042.7066.6094.1446.60119.70
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities15.9042.7041.6173.1617.0144.13
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock23.72-1.180.513.961.870.09
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock23.72-1.180.513.961.870.09
Proceedsfrom Stock Options0.07-1.180.290.84-0.370.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities23.72-1.180.513.961.870.09
Exchange Rate Effect0.00-0.01-0.100.00-0.100.13
Net Change in Cash10.040.123.3028.80-17.38-2.71
Free Cash Flow-29.58-41.39-38.72-48.31-36.17-47.11

Revenue breakdown

License and Service2024: 90.68M
Revenue from Contracts with Collaborators2024: 24.02M 2025: 48.47M
United States2024: 114.70M 2025: 48.47M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3023.91%1.3M5.6M260.41K
2026-10-1525.65%1.4M5.6M374.31K
2026-09-3022.10%1.2M5.6M369.38K
2026-09-1516.94%0.9M5.6M346.46K
2026-08-3118.43%1.0M5.6M347.29K
2026-08-1419.36%1.1M5.6M328.16K
2026-07-3121.14%1.2M5.6M311.32K
2026-07-1516.29%0.9M5.6M171.49K
2026-06-3011.95%0.7M5.6M148.01K
2026-06-1512.51%0.7M5.6M143.45K
2026-05-2932.19%0.8M2.4M136.30K
2026-05-1520.93%0.5M2.4M196.41K
2026-04-3019.49%0.5M2.6M204.06K
2026-04-1519.69%0.5M2.6M205.24K
2026-03-3120.13%0.5M2.3M197.63K
2026-03-1319.66%0.5M2.3M177.40K
2026-02-2718.90%0.4M2.3M153.37K
2026-02-1316.93%0.4M2.3M56.79K
2026-01-3014.49%0.3M2.3M49.44K
2026-01-1513.64%0.3M2.3M46.23K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-108-KCurrent report2026-11-10SEC
2026-11-1010-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-06SCHEDULE 13G/ASEC
2026-11-06SCHEDULE 13GSEC
2026-10-29SCHEDULE 13D/ASEC
2026-10-288-KCurrent report2026-10-27SEC
2026-10-08SCHEDULE 13D/ASEC
2026-09-288-KCurrent report2026-09-25SEC
2026-09-28SCHEDULE 13D/ASEC
2026-09-254Statement of changes in beneficial ownership of securities2026-09-23SEC
2026-09-254Statement of changes in beneficial ownership of securities2026-09-23SEC
2026-09-254Statement of changes in beneficial ownership of securities2026-09-23SEC
2026-09-254Statement of changes in beneficial ownership of securities2026-09-23SEC
2026-09-254Statement of changes in beneficial ownership of securities2026-09-23SEC
2026-09-254Statement of changes in beneficial ownership of securities2026-09-23SEC
2026-09-254Statement of changes in beneficial ownership of securities2026-09-23SEC
2026-09-238-KCurrent report2026-09-23SEC
2026-09-223Initial statement of beneficial ownership of securities2026-09-16SEC
2026-09-16DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-10-27SEC
2026-09-168-KCurrent report2026-09-16SEC
2026-09-118-KCurrent report2026-09-10SEC
2026-09-098-KCurrent report2026-09-09SEC
2026-09-04DNotice of sales of securities on Form D (Regulation D)SEC
2026-09-03PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-09-03SEC
2026-09-038-KCurrent report2026-09-03SEC
2026-08-264Statement of changes in beneficial ownership of securities2026-08-24SEC
2026-08-264Statement of changes in beneficial ownership of securities2026-08-24SEC
2026-08-264Statement of changes in beneficial ownership of securities2026-08-24SEC
2026-08-268-KCurrent report2026-08-24SEC
2026-08-264Statement of changes in beneficial ownership of securities2026-08-24SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
D. E. Shaw & Co., Inc.8.38%
683 Capital Management, LLC8.02%
DeepCurrents Investment Group LLC7.70%
Context Capital Management, LLC5.92%
Worth Venture Partners, LLC5.12%
FMR LLC4.76%
Kalehua Capital Management LLC4.56%
AQR CAPITAL MANAGEMENT LLC3.20%
GSA CAPITAL PARTNERS LLP3.07%
WOLVERINE ASSET MANAGEMENT LLC2.64%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND1.41%
Fidelity Small Cap Index Fund0.79%
Fidelity Nasdaq Composite Index Fund0.54%
VANGUARD EXTENDED MARKET INDEX FUND0.46%
VANGUARD RUSSELL 2000 INDEX FUND0.42%
Fidelity Extended Market Index Fund0.32%
iShares Biotechnology ETF0.31%
Schwab U.S. Small-Cap ETF0.20%
Schwab Small-Cap Index Fund0.17%
Invesco RAFI US 1500 Small-Mid ETF0.11%

OakChart. GOSS. Cached 15 minutes.

Some panels did not load: insider.